Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson’s Disease Vaccine against Alpha-Synuclein • PD01A was Safe and Well Tolerated: Primary Endpoint of Phase I „Boost“ Study Met • Immune Response was Seen in 86% of Patients, Resulting in an Increase of Responder Rate after Boost Immunization • PD01A-induced Antibodies Preferentially Bind to Fibrilic Alpha-Synuclein (aSyn) • Data will be Presented at the Poster Tour of Leading Abstracts at the 4th World Parkinson Congress in Portland, Oregon, USA on September 21

VIENNA, Austria, September 07, 2016 — AFFiRiS AG announced today results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE® PD01A, an active vaccine against Parkinson’s disease (PD). The study was

Weiterlesen